Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. The company has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease (MRD). The improved sensitivity of the Foresight MRD assays can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumors and B-cell malignancies.
Location: United States, Illinois, Aurora
Total raised: $58.75M
Investors 2
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Civilizati... | civilizati... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.04.2023 | Series B | $58.75M | Agent Capi... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 27.04.2023 | Foresight Diagnostics Nabs $58.75M Series B | AURORA, CO, Foresight Diagnostics announced today that it has closed an oversubscribed Series B fi... | vcnewsdail... |
| 27.04.2023 | Foresight Diagnostics Raises $58.75M in Series B Financing | Foresight Diagnostics, an Aurora, CO-based developer of cancer detection tests, raised $58.75M in Se... | finsmes.co... |
| - | Foresight Diagnostics | “The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earli... | fastfounde... |
| - | Healthcare hires of note | These job announcements are intended to highlight some of the hiring news over the past month and ar... | medcitynew... |